US Health Secretary RFK Jr plans to expand access to unapproved peptides, despite warnings from health experts about the limited evidence supporting their use.
Experts have cautioned that the drugs have not been adequately assessed in clinical trials involving humans. They also say the potential long-term effects remain unknown.
The concerns centre on the lack of established evidence about the safety and effectiveness of the peptides. While the proposed expansion would make them more accessible, the supplied information does not specify how access would change or when any measures would take effect.
Health experts’ warnings highlight the uncertainty surrounding the drugs as the US considers broader access. Further details about the policy and its implementation have not been provided.
